Hospira Vinorelbine Tartrate 50 mg/5 mL Injection vial

국가: 오스트레일리아

언어: 영어

출처: Department of Health (Therapeutic Goods Administration)

지금 구매하세요

공공 평가 보고서 공공 평가 보고서 (PAR)
30-11-2017

유효 성분:

vinorelbine tartrate, Quantity: 13.85 mg/mL

제공처:

Hospira Australia Pty Ltd

INN (International Name):

Vinorelbine tartrate

약제 형태:

Injection

구성:

Excipient Ingredients: water for injections

관리 경로:

Intravenous

패키지 단위:

1 X 5 mL

수업:

Medicine Listed (Export Only)

처방전 유형:

Not scheduled. Not considered by committee

치료 징후:

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Vinorelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Vinorelbine is indicated in combination with cisplatin.

제품 요약:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

승인 상태:

Licence status A

승인 날짜:

2008-05-21